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Abstract
Extra-cellular matrix (ECM) components are important and their stabilization is significant in
maintaining normal healthy joint environment. In osteoarthritis (OA), ECM components are altered
and indicate disease progression. The joint ECM is composed of proteoglycans (aggrecan, perlecan,
inter α-trypsin inhibitor), glycoproteins (fibronectin, lubricin, COMP) and collagen types (most abun-
dantly collagen type II) which represent structural and functional transformation during disease
advancement. ECM investigation revealed significant biomarkers of OA that could be used as a diag-
nostic and therapeutic tool in different canine orthopedic diseases. This review deliberates our cur-
rent findings of how the components of ECM change at the molecular level during disease pro-
gression in canine OA.
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Introduction
Osteoarthritis (OA) is one of the most prevalent
causes of joint degeneration, lameness, pain, and
chronic physical disability in dogs despite advanced
diagnostic approaches and modern therapies. Canine
diseases, such as: elbow dysplasia, hip dysplasia (HD),
poly-arthritis and cranial cruciate ligament (CCL)
rupture together with medial meniscus are major risk
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factors of OA. OA requires intensive and long term
treatment putting financial strain on pet owners. For
canine CCL disease and stifle joint OA alone, the
annual cost was estimated to be several billion dollars
(Wilke et al. 2005).
Why are dogs important in OA research? Animal
models were used in order to study human OA. In
fact, these experimental models provide valuable ad-
vantages and significant information in comparison
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with human OA research. The dog model is one of the
frequently used animal models for OA exploration,
since dogs have anatomical, clinical and therapeutic
similarities to human OA along with arthroscopy pos-
sibilities (Cook et al. 2010). Therefore, these features
make the dog an ideal species to study human OA.
For this purpose, OA was developed through surgical
induction of CCL (Pond and Nuki 1973) and meniscal
transection (Luther et al. 2009) in dogs. Other surgi-
cal and chemical induction models were also delin-
eated (Cook et al. 2010). Due to the close resem-
blance of the dog model to human OA, we focused
only on the dog OA model rather than other species,
such as sheep, goat, rat and horse.
Biomarkers are commonly used to diagnose dis-
eases. However, reliable biomarkers for canine OA
have yet to be discovered. Therefore, one of the goals
of ongoing studies in the field of veterinary and hu-
man orthopedics is to discover biomarkers for early
diagnosis and therapy of OA. Biomarkers are measur-
able indicators for the specific biological state. Par-
ticularly, they reflect the presence, risk, or stage of
a disease. In the clinic, biomarkers can be implemen-
ted as a diagnostic, prognostic and therapeutic tool
(Rifai et al. 2006). Biomarkers point out the pharma-
cological response to therapeutic interventions. Bio-
markers can be categorized into “dry” and “wet sol-
uble” biomarkers. Radiographs, magnetic resonance
imaging (MRI), computed tomography (Spector et al.
1992) and ultrasound are dry biomarkers, whereas
genetic (DNA, RNA) and biochemical (protein, pro-
tein peptides, carbohydrate and metabolites) mol-
ecules are wet soluble biomarkers (Kraus et al. 2011).
Radiography is usually used in diagnosing and
monitoring of dog OA. MRI and CT scans are more
sensitive than radiography. Nevertheless, their imple-
mentation is associated with high cost and the prob-
lem of availability. Likewise, Arthroscopy provides
a magnificent internal view of articular cartilage but
this is an invasive technique.
During OA, catabolic activities increase compared
to anabolism in articular cartilage, resulting in signifi-
cant loss of extra-cellular matrix (ECM) components.
The major components of cartilage are proteoglycans,
collagens, hyaluronan, and glycosaminoglycans along
with non-collagen glycoprotein components such as:
lubricin and cartilage oligomatrix protein (COMP).
The loss of ECM is a main characteristic of cartilage
destruction in OA. Hence, investigation of bio-chemi-
cal changes in ECM is believed to be an important
factor in OA pathology. Due to these changes, a few
discharged fragments could ultimately be assessed in
urine, blood plasma, serum and synovial fluid (Ol-
iviero et al. 2009). Multiple serological assays have
been developed for the detection of OA. They permit
the detection of fragments, including cytokines, pro-
teoglycans, collagen and many others. These robust
parameters represent disease severity and therapeutic
interventions. Similarly, ELISA is also used to exam-
ine the biochemical marker, where antibodies react
against different antigens in different biological fluids.
The literature provides a number of publications on
the subject of serological assays for OA biomarker
research in dogs. The current review summarized all
of the canine OA biomarkers in Table 1 regarding
protein and carbohydrate.
Collagen type II
Collagen type II is one of the major elements of
the cartilage ECM, structurally composed of three
identical collagen h1 chains in a triple helix, excep-
tionally N-, and C-telopeptides. The key function of
this collagen is to safeguard the cartilage. This col-
lagen is abnormally degraded in OA. One study meas-
ured SF antibody titers of collagen type I and II in
stifle joint disease CCL rupture (partial or complete)
accompanied with OA. The antibody titers of collagen
type I and II were significantly increased in SF, es-
pecially in dogs with secondary OA as compared to
the control dog group. Augmentations to collagen
autoantibodies in SF were not precise for the kind of
joint disorder. It was doubtful that anti-collagen anti-
bodies had an initial dynamic role in CCL weakness
(De Rooster et al. 2000).
Matrix metalloproteinase (MMP) family members
play a pivotal role in collagen type II degradation
(Chung et al. 2004). In dog OA cartilage, mRNA ex-
pression of MMP -2 and -9 was found to be elevated
(Clements et al. 2009). Moreover, there was clear evi-
dence that elevated canine MMP -2 and -9 activities
were present in CCL rupture SF (Boland et al. 2014)
(Rabillard et al. 2012). Different members of the
MMP family (MMP collagenases -2, -3, -9 and -13)
involved in initial collagen degradation (Settle et al.
2010) (Hegemann et al. 2003). Therefore, MMP -2, -3
and -9 are potential biomarkers in canine OA SF.
C2C is a concrete product resulting from collagen
type II breakage. In an ACLT model, collagen type II
neoepitope was increased in canine urine and its con-
centration was elevated in canine cartilage explant
after IL-1f-stimulation. Nevertheless, the collagenase
inhibitors suppressed the elevation of collagen type II
neoepitope (Matsukawa et al. 2013). Consequently,
this was shown to be a progressive step towards
a therapeutic approach. The collagenases break col-
lagen type II at approximately one quarter of the
length of the molecule away from the C-terminus. As
a consequence of this cleavage, l and L length
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Table 1. Biomarkers used clinically in canine OA, including their specificity and method of detection.
Specificity
OA Diseased Healthy
Biomarker Sample Number of Method of
type type animals detectionFragment Reference
Collagen
Type II
Autoantibodies ↑ ↑ CCL SF 82 dogs ELISA (De Rooster et al. 2000)
























(Settle et al. 2010)
COMP COMP ↑ Serum 16 OA dogs
+ 5 control
dogs






ELISA (Qi and Changlin 2006)
Fibronectin (V+C)- ↑ SF 26 OA dogs
+ 22 control
dogs
ELISA (Steffey et al. 2004)





ELISA (Venable et al. 2008)
↓ SF 49 dogs ELISA (Plickert et al. 2013)








12 dogs ELISA (Budsberg et al. 2006)
Chondroitin
sulfate




ELISA (Nganvongpanit et al.
2008)




ELISA (Nganvongpanit et al.
2008)




ELISA (Johnson et al. 2001)
(Johnson et al. 2002)
7D4 ↑ CCL SF ELISA (Johnson et al. 2001)





Serum 12 dogs ELISA (Budsberg et al. 2006)
5D4 ↓ SF ELISA (Matyas et al. 2004)
(Hegemann et al. 2002)
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Biomarker Sample Number of Method of
type type animals detectionFragment Reference
Aggrecan aggrecan
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(Hurlbeck et al. 2014)




ELISA (Boland et al. 2014)
fragments are released. The l fragment holds both
C2C neo-epitope or Col 2-3/4C (long monomers) par-
ticular to collagen type II (Poole et al. 2004) and C1,
2C or Col2-3/4C (short monomers) that are present in
both type I and type II collagen (Billinghurst et al.
1997). C2C is basically present in hyaline cartilage,
intervertebral disc, and in minute quantities in other
tissues (Poole et al. 2004).
This raises a relevant question whether OA
pathogenesis is accompanied by oxidative stress. The
Pond-Nuki model was designed to check the role of
oxidative stress in OA development. OA was experi-
mentally induced by anterior cruciate ligament tran-
section in 7 dogs. Analysis of preoperative and pos-
toperative (interval of 30, 60 and 105 days) serum
catalase displayed climax activity on day 60. In con-
trast, malondialdehyde and C2C concentration were
increased uninterruptedly throughout the experiment.
This indicates to a possible relation between oxidative
stress and cartilage obliteration (Goranov 2007).
There was no strong evidence that C2C could be
applied as a diagnostic biomarker in canine serum and
urine. A cross-sectional study was conducted to com-
pare C2C concentration in canine serum, urine, and
SF, between clinically developed stifle joint OA in
CCL disease and a control group. Fragment correla-
tion was checked with disease severity. C2C or Col
2-3/4C concentration was measured using a commer-
cially available ELISA kit. Lameness, osteophytosis
and joint effusion were important (p<0.05) par-
ameters, recorded in a naturally occurring diseased
group. However, there was no significant correlation
between C2C and clinical stifle joint OA (p>0.05).
C2C was not a cause of OA development, and there-
fore could not be used as a clinical biomarker (Hay-
ashi et al. 2009). However, decreased levels of C2C
and hyaluronic acid were better indicators of clinical
disease improvement in canine serum after hip OA
(Vilar et al. 2016). In a beagle OA model, plate-
let-rich plasma and adipose-derived mesenchymal
stem cells played a substantial role in the improve-
ment of ECM (collagen and glycosaminoglycan) (Yun
et al. 2016).
In contrast to the above observations, another
study noticed that C2C (Col 2-3/4C) concentration
was increased in canine synovial fluid (Chu et al.
2002). A cross-sectional clinical study was conducted
on canine elbow dysplasia with medial coronoid
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disease (Valiyaveettil et al. 2005). The mean (+ SD)
C2C concentration in MCD dogs was remarkably
higher (112.3 + 24.8 ng/ml) than in the control group
(76.1 + 16.9 ng/ml; P< 0.05). Therefore, C2C concen-
tration in SF might be a potential biomarker for diag-
nosis of the degree of articular cartilage damage with
MCD (Prink et al. 2010).
Coll2-1 and Coll2-1NO2 are the degradation prod-
ucts of collagen type II that can indicate both disease
succession and activity (Henrotin et al. 2007). A study
was conducted to measure Coll2-1 and Coll2-1NO2
during OA development after anterior cruciate liga-
ment transection in dogs. Immunoassays depicted
high serum concentrations with P values <0.001 and
<0.05 respectively. The level of Coll2-1NO2 showed
a constant increase and reached its peak level after
6 and 8 weeks of surgery. It was also associated with
osteophyte formation and reflected oxidative stress in
OA (Henrotin et al. 2012).
The carboxy-terminal cross-linked fragments of
collagen type II (CTX-II) showed an age dependent
pattern. CTX-II was increased in SF (Hurlbeck et al.
2014) and serum (Schoenherr et al. 2010) of juvenile
dogs. In a knee transection canine OA experimental
model, CTX-II concentration in SF was remarkably
higher in an affected joint compared to a contra-lat-
eral control joint (Matyas et al. 2004).
Thiol-dependent enzyme cathepsin K reacts in
a normal acidic pH environment that was evaluated to
be produced by OA chondrocytes and was thought to
play a major role in cartilage breakdown and ag-
grecans (Konttinen et al. 2002). Cathepsin K was in-
volved in hyaline cartilage destruction as well as calci-
fied cartilage and sub-chondral bone resorption at the
earliest stage of dog OA (Pelletier et al. 2004). In OA
cartilage, cathepsin K protein and its gene expression
were remarkably increased in the superficial zone in
comparison with normal cartilage (Pelletier et al.
2005). In the canine OA model, treatment with
licofelone (non-steroidal anti-inflammatory drug)
(Pelletier et al. 2004) and tiludronate (bisphosphon-
ate) (Moreau et al. 2011) considerably decreased
cathepsin K activity. Cathepsin K inhibitor
(SB-553484) treatment reduced subjective gross and
calculated degeneration scores by 29% and 46% re-
spectively in dogs. Histo-pathologic analysis indicated
that total tibial degeneration score decreased about
21%. In urine samples, biomarkers of collagen type
I and II were decreased, which is a direct outcome of
bone and cartilage degradation (Connor et al. 2009).
These results appeared to show that cathepsin
K played a key role in joint disability and lameness
and its level decreased after treatment. It is generally
believed that collagen fragmentation occurs during
OA and these fragments were investigated as valuable
diagnostic biomarkers. Hence, Cathepsin K, a less
abundant component of the cartilage, can be a better
diagnostic biomarker in relation to collagen type II
fragments.
Collagen type I h2-chain (COL1A2) and collagen
type III h1-chain (COL3A1) increased in OA carti-
lage relative to the control cartilage. In this study,
elevated MMP-2, -9 and -13 gene expressions were
assessed by reverse transcriptase polymerase chain re-
action. Radio-graphically assessed OA severity could
be correlated with cartilage gene expression (Clem-
ents et al. 2009). The relative increase in matrix metal-
loproteinase with collagens displayed its anabolic ef-
fect on collagens in canine OA cartilage. It is also
interesting to know that MMP-13 was thought to be
a major collagenase in OA cartilage and was basically
responsible for collagen type II cleavage (Kevorkian
et al. 2004).
Glyco-proteins
Cartilage oligomeric matrix protein (COMP)
COMP, also known as thrombospondin 5, is pres-
ent abundantly in the synovium, tendon, cartilage,
serum, and SF. COMP not only interacts with col-
lagen types (I, II and IX) but also supports collagen
types I and II in fibril formation. Therefore, it plays
a fundamental role in the assembly, solidarity and
safeguarding of the cartilage ECM (Chu et al. 2015).
Magnetic resonance imaging (MRI) is a useful
supplementary tool accompanied with different prac-
tical biomarkers in order to detect articular cartilage
degradation in dogs at its earlier stage. An elevated
level of COMP was noticed in serum after intensive
training indicating a potential relationship of COMP
with knee cartilage degradation measured with MRI
(P<0.01). However, the SF COMP value did not show
any difference between normal and abnormal MR
imaging (P>0.05) (Qi and Changlin 2007). In human
OA, COMP correlation with disease severity was es-
timated by MRI (Hunter et al. 2007) but it did not
exhibit any relationship with inflammatory biomarkers
(Skoumal et al. 2006).
What is the effect of exercise on COMP? Strong
physical activities, for example a marathon race, in-
creased the concentration of COMP in serum (Ander-
sson et al. 2006). Similarly, a higher COMP level was
recorded in serum and SF after strenuous exercise,
which ultimately reached its climax level after 4 and
6 weeks respectively in dogs. Meanwhile, changes in
knee cartilage were evaluated with MRI examination
(Qi and Changlin 2006). An increased COMP level at
its earlier stage was observed, which might be the re-
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sult of cartilage injury. Therefore, COMP could be
considered as a sensitive biomarker in articular carti-
lage injury.
In one study, the value of COMP concentration
was found to be significant (P=0.019) in OA dog;s
serum compared to a control group. After intramus-
cular treatment with poly-sulfated glycosaminoglycan
(PSGAG), COMP concentration was decreased
(p<0.001) in OA dogs in comparison with healthy
dogs. The analyzed improvement in lameness might
be a response to therapy (Fujiki et al. 2007). Thus
COMP could be used to monitor disease therapy and
also as a diagnostic biomarker in OA dogs.
Canine COMP concentration was elevated in
serum (44.9 ,g/ml) and synovial fluid (401.7,g/ml)
compared to the control group (31.3 and 298.7 9 ,g/ml
respectively) after naturally occurring OA (Misumi et
al. 2002). COMP value was also increased after ex-
perimentally induced OA (meniscectomy) (Lindhorst
et al. 2000) (Carlson et al. 2002). There was therefore
clear evidence that COMP concentration was raised
initially after meniscectomy in SF and remained the
same during 12 weeks of follow up (Lindhorst et al.
2000). One study indicated decreased COMP concen-
tration in SF after meniscal injury and correlation was
observed between COMP and canine meniscal injury
(Girling et al. 2006).
Fibronectin
Fibronectin (FN), a higher molecular weight
glycoprotein, is involved in a variety of cellular pro-
cesses, including migration, adhesion, proliferation
and differentiation. It is a major component of ECM,
uses as a substrate for cell attachment (Bager et al.
2016). Chondrocytes are the main source of FN in OA
cartilage. It was shown that total FN was increased
directly with extra domain B (ED-B+) FN in OA car-
tilage. FN, together with collagen type VI, might per-
form a role in matrix-matrix cohesion and cell-matrix
adhesion on agarose-cultured chondrocytes extracted
from normal adult canine articular cartilage. Im-
munohistochemistry together with dual channel
microscopy and digital image processing showed
co-localization between FN and collagen type VI in
the pericellular microenvironment regardless of a re-
taining mechanism in articular cartilage chondrocytes
(Scanzello et al. 2015).
The subcuticular connective tissues are most sen-
sitive in dogs. Matrix metalloproteinase inhibitors
(MMPi) were administered in dogs, which ultimately
became the cause of connective tissue alternation
known as “fibrodysplasia”. Fibrodysplastic tissues
showed significant activation and secretion of col-
lagens (type III and I) after ultra-structural analysis.
Immuno-histo-chemistry indicated increased levels of
FN and transforming growth factor f (Westwood et al.
2009). Therefore, MMPi-induced fibrodysplasia is
also a risk factor of musculoskeletal problems in dogs.
Fibronectin protein folds itself into a series of
globular homologous repetitions of three different
types I, II and III, comprises of 45, 60, and 90 amino
acids respectively. Different cell types produce differ-
ent multiple iso-forms of FN encoded by a single
gene. There are two iso-forms of FN, one containing
the V domain and another containing the ED-A do-
main employed in canine OA and human RA respect-
ively. The (V+C)- is an iso-form of FN that lacks I-10,
III-15 and domain V segments. Furthermore, it ac-
counts for 55-80% of total FN tissue in articular carti-
lage (Stoffels et al. 2013). Although (V+C) – iso-form
was present solely in cartilage, its presence in synovial
fluid indicated its cartilage origin and proved it as
a potential biomarker in order to observe canine OA.
An elevated level of (V+C) – was noticed in canine
SF in a contra-lateral knee suffering from CCL rup-
ture. Thus, it might represent earlier changes in knee
joint injury compared to a healthy joint. Nevertheless,
there were alterable measurements between the con-
trol and diseased group. This was possible due to joint
effusion in the affected knee joint that made it a less
applicable clinical biomarker (Steffey et al. 2004). On
the other hand, FN iso-form comprised with ED-A
domain was more expressed after the stimulation of
cytokines, hormones, growth factors and stress in dif-
ferent pathological diseases, including rheumatoid ar-
thritis (RA) (Przybysz et al. 2009). This iso-form was
particularly over expressed in SF, plasma and articular
cartilage of RA patients in comparison to OA or fi-
brous RA. For this reason it is a suitable biomarker in
RA disease (Miyamoto et al. 2002) (Przybysz et al.
2009). In RA patients, a direct correlation was noticed
between ED-A and progressive joint destruction in
SF. Therefore, ED-A in SF might be an indicator of
joint destruction during RA (Przybysz et al. 2009).
Fibronectin fragments were not identified in ca-
nine SF and serum. However, numerous FN frag-
ments (N-terminal FN) were identified in human OA
and RA, which were produced by ADAM-8-mediated
after FN cleavage at the Ala/Val site. The resulting
FN fragments VYQP and VRAA neo-epitopes were
therefore recommended as potential biomarkers.
These neo-epitopes were further analyzed in OA car-
tilage and were co-localized in the area of aggrecan
loss. VYQP neo-epitopes induced cartilage destruc-
tion (Zack et al. 2006) (Zack et al. 2009). Rac1 is
needed for FN fragments to induce signaling and to
increase chondrocyte MMP-13 production. Rac1 has
the ability to stimulate MMP-13 production so that it
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can perform an important function in OA cartilage
destruction (Long et al. 2013). Furthermore, pro-in-
flammatory factors (IL-1f, IL-6 or FN fragments)
stimulate meniscus cells to produce more metallop-
roteinases as well as catabolic gene expression. In fact,
stimulation of the meniscus can enhance the OA de-
velopment process after joint injury; there is an in-
creased production of chemokines, cytokines and
matrix degrading enzymes (Stone et al. 2014).
Lubricin
Lubricin, a lubricating and superficial zone
glycoprotein, is encoded by the PRG4 gene (Reesink
et al. 2016). It has a central protective role in cartilage
against friction-induced wear. Recent research has re-
vealed its important role both in cell adhesion and
proliferation. It has various functions in articular
joints and tendons, such as surface protection and
synovial cell growth (Szychlinska et al. 2016).
The role of lubricin is quite understood in human
OA (Musumeci et al. 2014) and in other species, in-
cluding the rabbit (Elsaid et al. 2005), rat (Musumeci
et al. 2015), sheep (Young et al. 2006), equine
(Reesink et al. 2016) and guinea pig (Wei et al. 2010).
Lubricin is widely distributed in different structures;
synovial fluid, articular cartilage, synovial fibroblasts,
synoviocytes, meniscus, tendons and ligaments
(Szychlinska et al. 2016).
The lubricating ability was evaluated by arthrot-
ripsometer oscillating latex opposed to polished glass
in in vitro analysis. In OA patients, the lubricating
tendency of lubricin was decreased in synovial fluid
compared to the healthy group (Jay et al. 2004). After
a joint injury, lubricin synthesis was increased (Jones
et al. 2009) in cartilage that was further isolated from
the synovial fluid in OA and RA patients. However,
liquid chromatography-MS analyses indicated that
RA patients contained different sialylation compared
to OA patients in which lubricin was enriched with
mono-sialylated types (Estrella et al. 2010). The sia-
lylation up-regulation indicated an inflammatory reac-
tion during which sialyic acids residues gained the
ability to increase lubrication.
In an animal model, treatment together with the
combination of lubricin protected articular cartilage
and prevented the process of OA development (Flan-
nery et al. 2009); its potential bio-therapeutic imple-
mentation in OA is recommended (Bao et al. 2011).
Lubricin played a significant role in reducing the glid-
ing fraction by repairing the canine flexor digitorum
prefunds tendon and maintaining tendon smoothness
(Taguchi et al. 2009) (Zhao et al. 2014). However, its
role in canine OA is yet to be evaluated.
Hyaluronan
Hyaluronic acid (HA) or hyaluronan, a polymer of
molecular mass up to 10 Daltons, is produced by
synovial fibroblasts and is composed of repeating dis-
accharidic units of D- glucuronic acid and
D-N-acetyl-glucosamine. HA is part of the normal
cartilage matrix where it has a central role in ECM
stabilization together with aggrecan interaction.
Moreover, HA has hydrodynamic properties and per-
forms fundamental functions in lubrication and osmo-
tic stability (Nusgens 2010). In an experimentally in-
duced OA, HA has a suppressive character in reduc-
ing chondrocyte apoptosis (Echigo et al. 2006).
Two-dimensional electrophoresis analysis re-
vealed hyaluronan-binding protein 2 (also known as
plasma hyaluronan binding protein, PHBP), which
has the ability to link with hyaluronan. This protein
was decreased in OA dog serum (Gharbi et al. 2013)
and displayed a strong attraction to negatively
charged substances, including hyaluronic acid, hepa-
rin and dextran sulfate. PHBP has the ability to inter-
act with glycosaminoglycans and, as a result, cuts
matrix proteins, such as fibrinogen and fibronectin
(Choi-Miura et al. 2001). Therefore, PHBP has
a catabolic effect on fibronectin and generates differ-
ent iso-forms in ECM (Steffey et al. 2004) (Przybysz
et al. 2009).
During canine orthopedic diseases, the level of
HA was lowered in serum (Nganvongpanit et al. 2008)
and synovial fluid (Venable et al. 2008). In contrast to
these findings, elevated serum (Sasaki et al. 2013) and
decreased SF levels of HA were noticed in human OA
(Li et al. 2009). In RA patients, a decreased HA level
was found in SF (Kosinska et al. 2015) and an elev-
ated concentration was noticed in serum
(Pothacharoen et al. 2006). In addition, HA molecular
weight was reduced in canine OA (Venable et al.
2008) similar to RA patients (Kosinska et al. 2015).
HA is a promising biomarker neither in human
RA nor in canine OA. The circulating HA level varies
with physical activity and diurnal periods, reducing its
effectiveness as a reliable clinical biomarker (En-
gstro¨um-Laurent and Ha¨llgren 1987). Hyaluronan
level decreased with the increase of disease severity
and its concentrations were not so consistent in differ-
ent OA stages; it is not therefore an ideal biomarker
for diagnostic purpose (Plickert et al. 2013).
Chondroitin Sulfate
Chondroitin sulfate (CS) binds covalently with ag-
grecan, leucine-rich proteoglycans, biglycan and de-
corin in ECM. CS contains different sequences of
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N-acetyl D-galactosamine 4/6 sulphate and
D-glucoronate residues, which are linked together
(Sˇima´neka et al. 2005). CS is a vital element in the
joint where it prevents space narrowing, decreases
joint swelling and effusion. It has an anti-inflamma-
tory role in chondrocytes and synovial fluid by inhibi-
ting nuclear translocation of nuclear factors kB
(NF-kB) (Iovu et al. 2008).
In canine hip dysplasia, the two isotopes (WF6
and 3B3) of CS were analyzed to evaluate the process
of OA. The results showed that CS epitope WF6 level
was higher (p<0.01) and 3B3 was lower (p<0.05) in
serum compared to the control group (Nganvongpanit
et al. 2008). The highest level of WF6 CS epitopes
indicated the process of joint degradation in OA,
whereas a decreased level of 3B3 showed less syn-
thesis of this isotope. It appears that imbalance of
these isotopes aggravates the disease process.
There was a noteworthy increase of 3B3 and 7D4
epitopes after naturally or experimentally induced
CCL rupture compared to normal SF. However, their
relationship to disease severity made their clinical
usage limited (Johnson et al. 2002). These epitopes
reached their peak levels after several months due to
CCL transaction and indicated a linear relationship
with disease progression regardless of CCL intra-ar-
ticular or extra-capsular reconstruction (Johnson et al.
2001).
Keratan Sulfate
Keratin sulfate (Stone et al. 2014) is an abundant
element in aggrecan and thus much effort was made
to develop a canine OA biomarker in the past. In
humans, KS level in serum was not related to knee
OA (Golightly et al. 2011). However, high serum KS
level was observed in old knee trauma patients.
Therefore, the serum level of KS in trauma patients
represented articular cartilage damage (Wakitani et
al. 2007). KS concentration fluctuated in canine SF
due to severity of cartilage degradation while serum
KS was increased after induced OA (Budsberg et al.
2006).
In SF, a lower level of KS 5D4 in canine OA was
detected through ELISA and this indicated its inverse
relationship with disease severity. The ratio of 5D4
KS/3B3 chondroitin sulfate was also decreased in SF
in contrast with 3B3 (+/-) revealing metabolic
changes in OA (Lindhorst et al. 2000) (Hegemann et
al. 2002). Likewise, KS epitope 5D4 level was reduced
in OA and RA in comparison with the healthy group
(Spector et al. 1992). Tibial plateau osteotomy did not
considerably change KS 5D4 expression, indicating
that surgery had a minimum effect on proteoglycan
metabolism (Girling et al. 2006). Tibial plateau os-
teotomy did not influence OA development. Current
evidence shows that KS is not a clinically reliable bio-
marker due to its inverse relationship with disease
progression and controversial research results.
Aggrecan
Aggrecan is the substantial proteoglycan of carti-
lage tissues and is responsible for hydrodynamic func-
tions, including weight bearing and elasticity. Further-
more, aggrecan (220 kDa) structure is made up of six
domains: globular 1 (G1), inter-globular (IG), globu-
lar 2 (G2), KS, CS and globular 3 (G3) (Nia et al.
2015). Both canine knee fibro-cartilage and hyaline
cartilage are dissimilar on a molecular basis, such as
gene expression and spatial aggrecan distribution, and
also on a concentration basis. These dissimilarities
were analyzed using real time PCR, immuno-fluor-
escence microscopy and ELISA (anti-aggrecan G1
antibody) respectively (Valiyaveettil et al. 2005). In
fact, aggrecan content decreased (40-50%) after OA
development in contrast to other small proteoglycans
(biglycan, fibromodulin and decorin), which increased
in canine cartilage (Liu et al. 2003) regardless of age.
Collagen type II and aggrecan mRNA ratios changed
in cartilage after experimentally induced OA (Matyas
et al. 2002).
Aggrecan 846 epitope is present on intact ag-
grecan molecules and is linked with CS at the level of
the G3 domain in cartilage. After a joint injury, epi-
tope concentration changed in SF and indicated de-
generative changes (Matyas et al. 2004). On the other
hand, the level of epitope in serum increased, while
KS remained unchanged (Matyas et al. 2004). The
increase of aggrecan 846 epitope in serum indicated
earlier joint injury; it could therefore be used as a di-
agnostic biomarker.
Aggrecan degradation plays an important role in
OA, in which newly formed C and N termini are pro-
duced after the cleavage of aggrecan by the reaction
of matrix metalloproteinases (proteolytic enzymes)
and aggrecanses respectively. C terminus containing
GAG was released out of the matrix after the cleavage
of the IG domain during aggrecan molecule break-
down. N terminus cleavage at the level of the Glu-Ala
bond generated ARGN and AGEG peptides which
were detected using polyclonal antibody (Gibson and
Briggs 2016). ADAMTS -4 and -5, also known as ag-
grecanase 1 and 2 respectively, produced fragments of
aggrecan at five different points which were recog-
nized in diseased cartilage (Arner 2002) (Nagase and
Kashiwagi 2003). MMPs were also responsible for ag-
grecan cleavage (Struglics et al. 2006). The resulting
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products (ARGN and AGEG) were valuable degra-
dation biomarkers only in canine SF. MMP-13 per-
formed an active role in aggrecan degradation and its
activity was reduced by using PF152 (MMP inhibitor)
in dogs; this could ultimately decrease aggrecan pept-
ides and cartilage lesions (Settle et al. 2010). The ag-
grecanases were actively involved in IGD cleavage at
earlier stages in OA joints. BC-3 and BC-14 aggrecan
metabolites (200-250Kd) were both able to differenti-
ate between early and late stages of OA (Innes et al.
2005). However, MMPs mediated cartilage degrada-
tion at later stages of OA (Little et al. 2002).
Conclusion
In the last two decades, efforts to discover a prac-
ticable solution for the diagnosis of human and canine
OA have intensified. Biomarkers detect cartilage pro-
teoglycan degradation and their resulting fragments,
in synovial fluid, serum, plasma and urine and can be
used to diagnose the disease, monitor its progression,
and to evaluate therapeutic response. Therefore, ef-
forts were focused on biomarker development. Dogs
are considered an ideal animal in OA research be-
cause dog OA models provide significant information
regarding OA diagnosis, pathogenesis and treatment.
Although outstanding work has been done towards
clinical biomarker development, the discovery of a re-
liable biomarker for OA remains elusive.
Different proteoglycan biomarkers are discussed
in this review paper to assess their specificity and cli-
nical use in canine OA. Researchers started to focus
on biomarker development from fragments of protein
in ECM, which restricted further research process on
OA. There is an urgent need to study other proteog-
lycans, such as perlecan and inter alpha trypsin inhibi-
tor and their possible involvement in canine OA. The
role of perlecan has already been appraised in human
OA (Tesche and Miosge 2004).
Researchers are now focusing on proteomic analy-
sis in OA; this method of research leads to more clari-
fication of cartilage ECM structure and degradation,
and scrutinizes more efficiently the proteins in SF,
serum and urine. Proteomics analysis has proven itself
as a milestone in developing a biomarker in OA until
now. Electrophoresis analysis is carried out to analyze
different proteins and peptides through matrix-assist-
ed laser desorption ionization-imaging mass spec-
trometry (MALDI-MS/MS). These abundant proteins
can be purified as diagnostic biomarkers through
ELISA and western blotting analyses.
Biomarkers are an indicator of disease severity
and therapeutic response; for example, the role of
poly-sulfated glycosaminoglycan treatment was
studied in OA and its effect on different biomarkers
(COMP, MMP-2, MMP-9 and CRP) was also inves-
tigated (Fujiki et al. 2007). Biomarkers are a valuable
tool in diagnosing OA at earlier and later stages. Ad-
ditionally, their implementation for the treatment of
OA is another positive aspect. For the future investi-
gation of the biomarkers of OA, integrating
glycol-proteomics analysis of carbohydrate and pro-
tein structure should be included in combination
rather than in isolation. Proteomics analysis was
started earlier in humans than in dogs to resolve the
OA problem; however, this analysis is very crucial in
resolving OA in canines as well. Therefore, concerted
efforts are required for proteomics analysis in canine
OA.
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